Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGB-10188 ± Zanubrutinib and BGB-10188 + Tislelizumab in B-cell Malignancies and Solid Tumors
CTR20220463Phase 2Completed
- Sponsor
- BeiGene
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bgb-10188 in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), follicular lymphoma (FL), marginal zone B-cell lymphoma (MZL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), sponsored by BeiGene. Started Mar 2022; status: completed.
02
Drugs
bgb-10188
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)follicular lymphoma (FL)marginal zone B-cell lymphoma (MZL)mantle cell lymphoma (MCL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on CTR20220463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220463.